Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutics, Inc. - Common Stock
(NQ:
HALO
)
68.03
-0.95 (-1.38%)
Streaming Delayed Price
Updated: 11:57 AM EDT, May 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutics, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
↗
August 01, 2024
Via
Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
↗
July 26, 2024
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Via
Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
↗
July 24, 2024
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.
Via
Investor's Business Daily
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
↗
July 22, 2024
There are signs that NASDAQ:HALO may be ready to breakout.
Via
Chartmill
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
↗
July 18, 2024
These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late.
Via
InvestorPlace
NASDAQ:HALO is showing good growth, while it is not too expensive.
↗
July 18, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing.
Via
Chartmill
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
↗
July 16, 2024
Via
Benzinga
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
↗
July 15, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?.
Via
Chartmill
NASDAQ:HALO Shows Potential for a Breakout.
↗
July 09, 2024
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective.
Via
Chartmill
Biotech Arvinas Stock Earns 82 RS Rating
↗
July 17, 2024
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.
Via
Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
↗
July 16, 2024
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
3 Biotech Stocks to Buy Now: Q3 Edition
↗
July 15, 2024
Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry.
Via
InvestorPlace
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
↗
July 12, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
↗
July 05, 2024
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
Via
InvestorPlace
3 Breakout Biotech Stocks on Track to Double by 2032
↗
July 01, 2024
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.
Via
InvestorPlace
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
↗
June 24, 2024
Via
Benzinga
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
↗
June 24, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
Via
Chartmill
UroGen Pharma Stock Earns 91 RS Rating
↗
June 27, 2024
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.
Via
Investor's Business Daily
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
↗
June 26, 2024
Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO).
Via
Chartmill
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
↗
June 24, 2024
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier.
Via
Investor's Business Daily
Arcellx Stock Earns Relative Strength Rating Upgrade
↗
June 21, 2024
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
Via
Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
↗
June 20, 2024
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.
Via
Investor's Business Daily
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
↗
June 19, 2024
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
The 3 Best Healthcare Stocks to Buy in June 2024
↗
June 15, 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.
Via
InvestorPlace
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
↗
June 14, 2024
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.
Via
Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
↗
June 12, 2024
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.
Via
Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
↗
June 11, 2024
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88.
Via
Investor's Business Daily
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
↗
June 09, 2024
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.
Via
Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
↗
June 07, 2024
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91.
Via
Investor's Business Daily
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
↗
June 07, 2024
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
